Proprietas
Proprietas is a venture capital firm based in Cape Town, South Africa, focused on startups in PropTech & Real Estate. This profile covers its focus and how founders can get in front of it in 2026.
Proprietas specializes in real estate investments and property management.
- Investment focus
- PropTech & Real Estate
- Location
- Cape Town, South Africa
- Team size
- 11-50
How to pitch Proprietas
The founders who hear back from Proprietas lead with traction and a clear ask that matches its stage, not a generic mass email. Build a targeted, verified list, write a personalized note, and track who opens it, all in one place.
Connect with Proprietas
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "Proprietas." Round Funded investor database, updated October 19, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/vc/proprietas
Frequently Asked Questions
What does Proprietas invest in?
Proprietas focuses on PropTech & Real Estate. Match your sector and stage before reaching out, then find similar active investors on Round Funded.
Where is Proprietas based?
Proprietas is based in Cape Town, South Africa. You can reach out from anywhere with a pitch that matches its focus.
How do I contact Proprietas?
Unlock a verified email for Proprietas and reach out with a personalized pitch on Round Funded. We show only deliverable contacts, so your outreach does not bounce.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.